Cancer Risk in Patients With Muscular Dystrophy and Myotonic Dystrophy
Carolina Maya‐González(Karolinska Institutet), Ann Nordgren(Karolinska University Hospital), Fulya Taylan(Karolinska University Hospital), Anna Skarin Nordenvall(Karolinska Institutet), Giorgio Tettamanti(Karolinska Institutet), Thomas Sejersen(Hong Kong Science and Technology Parks Corporation)
Cited by 7
Related Papers
Disease Modifying Therapies for the Management of Children with Spinal Muscular Atrophy (5q SMA): An Update on the Emerging Evidence
|Drug Design Development and Therapy|2022|57
Implementing precision medicine in a regionally organized healthcare system in Sweden
|Nature Medicine|2022|42
The risk of developing a meningioma during and after pregnancy
|Scientific Reports|2021|28
Monoallelic and bi-allelic variants in NCDN cause neurodevelopmental delay, intellectual disability, and epilepsy
|The American Journal of Human Genetics|2021|23
Diagnostic yield and clinical impact of germline sequencing in children with CNS and extracranial solid tumors—a nationwide, prospective Swedish study
|The Lancet Regional Health - Europe|2024|19